MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
43.41
-0.66 (-1.51%)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases
Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy.
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&P 500 also fell, dropping, 0.13% to 4,352.49.
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also rose, gaining, 0.09% to 4,362.35.
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday Following the market opening Monday, the Dow traded up 0.21% to 34,133.62 while the NASDAQ rose 0.37% to 13,528.32. The S&P 500 also rose, gaining, 0.19% to 4,366.66.
MoonLake Immunotherapeutics (NASDAQMLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week results, in which the primary endpoint was met with 29 percentage points delta
